13–20 minutes
NCCN HCT Guidelines v2.2026 (April 3, 2026)
Mechanism & Purpose
- Conditioning eliminates malignant marrow + immunosuppresses recipient → allows donor engraftment
- Donor T-cells attack residual malignancy (GvL/GvT effect) — potentially curative
- Risk: GVHD, infections, NRM, organ toxicity
- GvL strongest in CML > AML/MDS > ALL > lymphoma
Indication
Donor Sources (Hierarchy & Key Points)
| Donor Type | HLA Match | Preference Rank | GVHD Risk |
|---|---|---|---|
| HLA-Matched Sibling (MSD) | 8/8 matched | 1st preferred | Lowest |
| HLA-Matched Unrelated (MUD) | 8/8 matched | 2nd (comparable to MSD) | Moderate |
| Haploidentical (Haplo) | ≥4/8 HLA loci | Expand access (PTCy makes feasible) | Higher — mitigated by PTCy |
| Mismatched Unrelated (MMUD) | 7/8 | Alternative when 8/8 MUD unavailable | Higher |
| Umbilical Cord Blood (UCB) | 4-6/6 HLA-A,B,DRB1 | Patients lacking matched donor | Less cGVHD, delayed engraftment |
CLINICAL PEARL: Donor AGE matters: Data from 1802 CIBMTR patients show donor age >30 years increases GVHD risk. Younger donors preferred when HLA-matched alternatives exist, especially with PTCy prophylaxis (NCCN v2.2026).
PHARMACIST WATCHPOINT: When reviewing donor workup, verify donor age and HLA resolution (8/8 at minimum for MUD). Flag any anti-HLA antibodies in recipient — DSA against donor antigens → high risk of graft failure.
Graft Source Comparison
| Source | Peripheral Blood (PBSC) | Bone Marrow (BM) |
|---|---|---|
| Collection | G-CSF mobilization + apheresis | OR under GA, posterior iliac crests |
| Engraftment | Faster (ANC recovery ~12 days) | Slower |
| cGVHD Risk | Higher | Lower — preferred in haplo/MMUD settings |
| aGVHD | Similar or slightly higher | Similar |
| Current Use | Dominant (most allo and all auto-HCT) | Preferred in haplo (haploidentical BM transplant) |
Donor Stem Cell Mobilization (NCCN HCT-4/HCT-4A)
- Minimum CD34+ Preferred Yield: ≥4 × 10⁶ CD34+ cells/kg
- Optimal CD34+ Yield: 4–5 × 10⁶ CD34+ cells/kg
- Yields <2 × 10⁶ CD34+/kg may have a risk of delayed engraftment. Higher yields → faster platelet AND neutrophil recovery. The allogeneic target is higher and starts at 4–5 × 10⁶/kg because you have only one collection opportunity with a healthy donor. If insufficient (<4 × 10⁶ CD34/kg): Add plerixafor OR proceed to bone marrow harvest
- NO chemotherapy used in allogeneic donors — risk to healthy individual
Hematopoietic Cell Mobilization Regimens
- Filgrastim (or FDA-approved biosimilar)
- Filgrastim 10 mcg/kg SC daily for 4-5 days (or split twice daily to reduce bone pain). Collect SC on Day 4 or 5
Risk Factors for Poor Mobilization
| Patient Factors | Treatment Factors |
|---|---|
| Older age | Prior fludarabine (lymphotoxic, depletes stem cells) |
| Extensive prior chemotherapy (>4 lines) | Prior lenalidomide therapy (especially ≥4 cycles) |
| Low baseline WBC (<4000/μL) | Prior radiation to marrow-containing regions |
| Bone marrow involvement at collection time | High cumulative alkylating agent exposure |
Rescue Strategies (NCCN HCT-4)
- Increase G-CSF dose or change to twice-daily dosing
- Add plerixafor ‘just-in-time’ to G-CSF (even after 1st apheresis day if <2 × 10⁶ collected). Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis.
- Switch to chemo-mobilization ± plerixafor
- Bone marrow harvest (refer to NMDP/Be The Match)
- Rest 2–4 weeks (if clinically feasible) before remobilization attempt
PLERIXAFOR DOSING: Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis. RENAL ADJUSTMENT: For CrCl ≤50 mL/min — reduce dose by 30% to 0.16 mg/kg (max 27 mg). Check renal function BEFORE each dose.
CLINICAL PEARL: WBC MONITORING TRICK: For chemo-mobilization, monitor daily WBC and peripheral blood CD34+ count starting Day 4 post-Cy. Initiate apheresis when WBC rising rapidly (nadir rebound). Many centers trigger by peripheral CD34+ count (target ≥10–20/μL by institutional protocol).
Conditioning Regimen (NCCN HCT-A)
- Intensity: MA, NMA, RIC. The intensity depends on age, performance status, comorbidities (HCT-CI), disease type, remission status, prior HCT.
- MA regimens preferred in young/fit patients with ALL (TBI-based regimens), AML, CML, MDS
- NMA/RIC is preferred in old/unfit, lymphoma (HL/NHL), CLL, plasma cell disorders (MM, plasma cell leukemia), prior autoHCT,
- Busulfan plasma exposure unit conversion: AUC 5000 uMxmin = 20.5 mgxh/L.1
Conditioning Regimen Selection Factors
- Patient age (chronological AND physiological/functional)
- ECOG/KPS performance status
- HCT-CI2 and pertinent comorbidities
- Disease type and remission status (including MRD status)
- History of prior HCT (prior auto-HCT → RIC preferred for allo)
- Graft source (UCB, haplo, MSD, MUD) and degree of HLA disparity
| Intensity | Definition / Examples | Clinical Use |
|---|---|---|
| MYELOABLATIVE (MA) | Causes IRREVERSIBLE (or near-irreversible) pancytopenia. HCT support REQUIRED to prevent aplasia-death. TBI ≥5 Gy single dose OR ≥8 Gy fractionated Busulfan >8 mg/kg PO (>6.4 mg/kg IV) or AUC equivalent | Young, fit patients with AML, ALL, CML, MDS seeking maximum anti-tumor effect and lower relapse risk |
| REDUCED INTENSITY (RIC) | Does NOT fulfill MA or NMA criteria. Cytopenias REQUIRE HCT support but alkylator/TBI doses are reduced vs MA. | Bridge between MA and NMA. Most common for older patients, prior allo-HCT, lymphoma, CLL, plasma cell disorders. |
| NON-MYELOABLATIVE (NMA) | Minimal cytopenia. If graft fails, autologous recovery occurs. TBI ≤2 Gy ± purine analog Total lymphoid irradiation + ATG | Older/comorbid patients. Relies heavily on GvL effect. Lymphoma, CLL, plasma cell disorders, 2nd transplant. |
Myeloablative (MA) Conditioning Regimens
| Regimen | Drugs & Doses | |
|---|---|---|
| Cy + TBI (TBI-Based) | Cyclophosphamide 60 mg/kg/day × 2 days TBI 12–13.2 Gy fractionated | Historical standard. Still used for ALL (TBI-based preferred). Cy order matters: Cy THEN TBI. |
| Flu + TBI | Fludarabine 30 mg/m²/day × 3 days → TBI 12 Gy fractionated OR Fludarabine 30 mg/m²/day × 4 days → TBI 8–12 Gy fractionated | Weigh relapse risk vs. toxicity. Less late effects vs. Cy+TBI. Used in ALL. Note: 4-day flu + 8–12 Gy TBI option added v1.2026. |
| Bu + Cy (BuCy) | Busulfan 3.2 mg/kg/day IV × 4 days Cyclophosphamide 60 mg/kg/day × 2 days | ⚠ Sequence MATTERS: BuCy ≠ CyBu. Cy before Bu = different toxicity. PK monitoring for Bu is preferred IV route. |
| Flu + Bu (FluBu4) | Busulfan 3.2 mg/kg/day IV × 4 days (12.8 mg/kg total) Fludarabine 30–32 mg/m²/day × 4–5 days | Most common MA allo regimen. Lower NRM vs. BuCy. PK-guided busulfan dosing preferred (AUC 60–100 mg×h/L). |
| Flu + Bu + Thiotepa (TBF-MA) | Thiotepa 5 mg/kg/day × 1–2 days Busulfan 3.2 mg/kg/day × 3–4 days Fludarabine 30–50 mg/m²/day × 3–4 days | Used in AML/MDS especially haplo settings with PTCy. Thiotepa excreted through skin — skin care protocol required. |
| Clofarabine + Bu (MA) | Clofarabine 20–40 mg/m²/day × 4–5 days Busulfan AUC 4000–5500 (or 3.2 mg/kg/day) × 4 days | For non-remission or refractory disease. Watch for systemic inflammatory syndrome (cytokine release) — concurrent steroids may prevent. |
| Flu + Treosulfan | Treosulfan 10 g/m²/day × 3 days Fludarabine 30 mg/m²/day × 5 days | Alternative to busulfan (MC-FludT.14/L trial: non-inferior to BuFlu in older AML/MDS pts). Less CNS toxicity than busulfan. Not widely available in US. |
| Etoposide + TBI (Ma regimen) | Etoposide 60 mg/kg × 1 dose TBI 12–13.2 Gy fractionated | Historical option for lymphoma or ALL. Dose etoposide on 25% adjusted body weight if obese. |
UCB-Specific MA Regimens
- Flu + Cy + TBI: Flu 30–45 mg/m²/day × 4d | Cy 60 mg/kg/day × 2d | TBI 13.2 Gy fractionated
- Flu + Thiotepa + TBI: Flu 40 mg/m²/day × 4d | Thiotepa 5 mg/kg/day × 2d | TBI 13.2 Gy fractionated
- Flu + Bu + Thiotepa (UCB): Thiotepa 5 mg/kg/day × 2d | Bu 3.2 mg/kg/day × 3d | Flu 50 mg/m²/day × 3d
- If MA conditioning planned for UCB recipient: Consider omidubicel-onlv (ex vivo nicotinamide-modified progenitor cells) to shorten engraftment time (Phase III: neutrophil recovery 12 vs. 22 days, P<0.001).
Reduced Intensity (RIC) Conditioning Regimens
| Regimen | Drugs & Doses | Notes |
|---|---|---|
| Flu + Mel (FluMel) | Fludarabine 20–36 mg/m²/day × 4–5 days Melphalan 100–140 mg/m² over 1–2 days | Widely used RIC. Melphalan dose is a NUANCED DECISION — team decides based on organ function, frailty, geriatric assessment. |
| Flu + Bu2 (FluBu2) | Fludarabine 30 mg/m²/day × 4–5 days Busulfan 3.2 mg/kg/day IV × 2 days OR 1.6 mg/kg/day IV × 4 days | Most common RIC busulfan-based. PK monitoring preferred (busulfan AUC still applies at lower doses). |
| Flu + Cy + TBI (NMA-RIC) | Flu 30 mg/m²/day × 5d (OR 25 mg/m²/day × 6d) Cyclophosphamide 14.5 mg/kg/day × 2 days TBI 2–4 Gy | Classic haploidentical BMT conditioning (Luznik 2008). Used with PTCy GVHD prophylaxis. |
| Flu + Mel + TBI | Flu 30 mg/m²/day × 5d (OR 25 mg/m²/day × 6d) Melphalan 70–140 mg/m² × 1–2 days TBI 2–4 Gy | ⚠ If using PTCy for GVHD prophylaxis: carefully evaluate melphalan and TBI doses. Mel dose is nuanced. |
| Flu + Mel + Thiotepa | Flu 40 mg/m²/day × 4d Melphalan 100–140 mg/m² × 1d Thiotepa 10 mg/m² × 1d | For haplo transplant. Low thiotepa dose here. Skin care required for thiotepa. |
| Flu + Bu + Thiotepa (RIC-TBF) | Thiotepa 5 mg/kg/day × 1 day Busulfan 130 mg/m²/day IV × 2 days (equivalent to ~3.2 mg/kg/day) Flu 30–40 mg/m²/day × 4 days | RIC version of TBF. Haplo or MUD setting. |
Flu Shortage Alternatives: Listed as alternatives due to intermittent US fludarabine shortages. Limited comparative data vs. Flu-based regimens. Choose based on institutional experience and GVHD prophylaxis compatibility.
| Category | Regimens without Fludarabine |
|---|---|
| Pentostatin-based | • Pentostatin + busulfan • Pentostatin + busulfan + cyclophosphamide • Pentostatin + TBI 4 Gy |
| Clofarabine-based | • Clofarabine + busulfan | • Clofarabine + melphalan ± thiotepa | • Clofarabine + TBI 2 Gy • Clofarabine + cyclophosphamide + TBI 2 Gy (with PTCy) ⚠ Systemic inflammatory syndrome reported — concurrent steroids may mitigate |
| Cladribine-based | • Cladribine + busulfan + ATG | • Cladribine + busulfan + TBI 2 Gy ⚠ Busulfan ± TBI 2 Gy may risk engraftment failure with cladribine |
| Cyclophosphamide-based | • Cyclophosphamide + TBI 5.5 Gy |
Non-myeloablative (NMA) Conditioning Regimens
| Regimen | Drugs, Doses | Notes |
|---|---|---|
| Flu + TBI 2Gy (NMA Classic) | Fludarabine 30 mg/m²/day × 3 days TBI 2 Gy (single fraction) | Classic NMA. Relies entirely on GvL. Best for indolent disease, older unfit patients. Autologous recovery if graft fails. |
| Flu + Cy ± Rituximab | Fludarabine 30 mg/m²/day × 3d Cyclophosphamide 750 mg/m²/day × 3d Rituximab: 375 mg/m² before transplant; then 1000 mg/m² on Days +1, +8, +15 after transplant | For CD20+ B-cell malignancies (CLL, indolent NHL). Rituximab added to exploit CD20+ residual disease. NMA intensity. |
Busulfan PK Monitoring (NCCN HCT-A)
- PK monitoring is REQUIRED for oral busulfan and PREFERRED for IV busulfan.
- Underexposure (relapse ↑ + reduced OS), and Overexposure (VOD/SOS ↑ + NRM ↑).
- Click here for Busulfan PK monitoring.
BUSULFAN + SEIZURE PPX: Do NOT use phenytoin as seizure prophylaxis with busulfan. Phenytoin induces CYP enzymes → increases busulfan clearance → underexposure → relapse risk. Use levetiracetam (preferred) or clonazepam/lorazepam.
CLINICAL PEARL: Busulfan dose for OBESE patients: mg/kg dosing → use 25% adjusted body weight (IBW + 0.25 × [TBW – IBW]). BSA dosing → use total body weight. NEVER dose on TBW for mg/kg regimens in obese patients.
Weight-Based Dosing (NCCN HCT-A, Table 7)
| Drug | Dosing Weight (Standard) | Dosing Weight (Obese TBW >120% IBW) |
|---|---|---|
| Busulfan (mg/kg dosing) | 25% Adjusted BW = IBW + 0.25(TBW–IBW) | Same: 25% Adjusted BW |
| Busulfan (BSA dosing) | BSA based on TOTAL body weight | Same |
| Carmustine (BCNU) | BSA based on TOTAL body weight | 25% Adjusted BW (if TBW >120% IBW) |
| Cyclophosphamide (Cy200) | Lesser of TBW or IBW | IBW if TBW >120% IBW |
| Cyclophosphamide (Cy120) | TBW or IBW | 25% Adjusted BW (if TBW >120% IBW) |
| Cytarabine (AraC) | BSA based on TOTAL body weight | Same |
| Etoposide (mg/kg) | 25% Adjusted BW | Same: 25% Adjusted BW |
| Etoposide (BSA) | BSA based on TOTAL body weight | Same |
| Fludarabine | BSA based on TOTAL body weight | Same |
| Melphalan | BSA based on TOTAL body weight | Same |
| Thiotepa | BSA based on TOTAL body weight (if TBW ≤120% IBW) | 40% Adjusted BW: IBW + 0.4(TBW–IBW) |
| Treosulfan | BSA based on TOTAL body weight | Same |
Special Situations & Contraindications in Conditioning Selection
| Clinical Situation | Conditioning Consideration |
|---|---|
| Significant Pulmonary Dysfunction | CAUTION with: HD busulfan, carmustine (BCNU), HD TBI. If DLCO <60% → pulmonary consult. BCNU pulmonary toxicity is >50% at 600 mg/m² in multi-agent regimens. |
| Significant Liver Dysfunction / Cirrhosis | HD busulfan + HD TBI → increased VOD/SOS risk. Cirrhosis with portal HTN = CONTRAINDICATION for allo-HCT. Dual alkylator regimens after inotuzumab/gemtuzumab → very high VOD risk. |
| Prior Inotuzumab or Gemtuzumab | Dual alkylator-based conditioning → VERY HIGH VOD/SOS risk. Defibrotide prophylaxis often used. Avoid if possible. |
| Prior Checkpoint Inhibitor (PD-1/PD-L1) | Increased GVHD risk pre- or post-HCT. Consider minimum 8–12 week washout window before conditioning start. |
| Prior Mogamulizumab | Increased GVHD risk after allo-HCT. 8–12 week washout recommended. |
| Thiotepa Use | Excreted through SKIN. Requires special skin care protocol: shower every 6–8h during and after infusion. Patients and staff education critical. |
| Sirolimus + Tacrolimus (Prophylaxis) with MA | Higher risk of VOD/SOS and thrombotic microangiopathy (TMA) when combined with MA conditioning. Monitor closely. |
| Prior Auto-HCT | RIC/NMA preferred for subsequent allo-HCT. Higher NRM with MA after prior auto-HCT. |
POST-TRANSPLANT CHIMERISM MONITORING (NCCN HCT-C)
- Complete donor chimerism: >95% donor cells in myeloid + lymphoid compartments
- Mixed chimerism: 5–95% donor cells
- Absent donor chimerism: <5% — high graft rejection/failure concern
- Declining chimerism in AML/MDS → signals relapse risk → alert team
- Monitor by peripheral blood PCR (STR-based, per NCCN HCT-2 update: STR genotyping required pre-transplant)
GVHD PROPHYLAXIS (NCCN HCT-B)
Prophylaxis by Donor Type
| Donor Setting | Preferred Regimens | Alternative Regimens |
|---|---|---|
| HLA-Matched (MSD or MUD) | • PTCy + Tacrolimus + MMF (Cat 1 for RIC — BMT CTN 1703) • CNI + MTX (Tacrolimus/MTX or Cyclosporine/MTX) • Tacrolimus + Sirolimus ± MTX | • PTCy + Cyclosporine (Cat 1 for RIC) • CNI + Abatacept + MTX (for MUD — ABA2 data) • ATG + CNI ± MTX or MMF • Alemtuzumab + CNI ± MMF or MTX • Ex vivo CD34 selection |
| Haploidentical (PREFERRED: PTCy-based) | • PTCy + Tacrolimus + MMF (STANDARD) • PTCy + Sirolimus + MMF | • Alemtuzumab + PTCy + Sirolimus or CNI • ATG + PTCy • Ex vivo CD34 selection or αβ T-cell depletion |
| HLA-Mismatched Unrelated (MMUD, PREFERRED: PTCy) | • PTCy + Tacrolimus + MMF • PTCy + Sirolimus + MMF • PTCy + Cyclosporine + Sirolimus | • CNI + Abatacept + MTX (7/8 MMUD) • ATG + PTCy • Ex vivo CD34 selection (7/8 MUD only) • Alemtuzumab + CNI ± MMF or MTX |
| Umbilical Cord Blood (UCB) | • CNI (Tacrolimus or Cyclosporine) + MMF (Standard for UCB — most experienced approach) | No PTCy standard for UCB at this time |
Key Clinical Trial Evidence
| Trial | Population / Result / Implication |
|---|---|
| BMT CTN 1703 (Bolanos-Meade, NEJM 2023) | RIC PBSC allo-HCT (MSD/MUD). PTCy + Tac + MMF vs. Tac + MTX. Result: superior 1-yr GVHD-free relapse-free survival (GRFS) with PTCy arm (52.7% vs 34.9%). Category 1 for RIC. |
| HOVON-96 (Broers, Blood Adv 2022) | Prospective randomized trial. PTCy + Cyclosporine for GVHD prophylaxis after HLA-matched PBSC. Category 1 for RIC. |
| ABA2 (Kean, Blood 2024) | Phase III: Abatacept + CNI + MTX in MUD and 1-allele MMUD (7/8). Significant reduction in severe aGVHD vs. CNI+MTX alone for MMUD. Abatacept FDA approved for aGVHD prophylaxis in MUD/MMUD. |
| MMUD PTCy Trial (Al Malki, JCO 2025) | Phase III: PTCy+Tac+MMF vs. standard (Tac+MTX) in MMUD PBSC. Superior 1-yr GRFS. Supports PTCy as preferred for MMUD. |
| Sirolimus/CSA/MMF (NMA) (Kornblit, Blood 2020) | Triple MMF/CSA/sirolimus superior to historical CSA/MMF in NMA with Flu/TBI 200–300 cGy + MMUD. |
PTCy Protocol Details
| Parameter | Details |
|---|---|
| Drug | Cyclophosphamide (post-transplant cyclophosphamide = PTCy) |
| Typical Dose | 50 mg/kg/day IV on Days +3 and +4 (post-transplant) |
| Mechanism | Eliminates rapidly proliferating alloreactive T-cells while sparing regulatory T-cells (Tregs) → tolerogenic immune reconstitution |
| Combination Partners | Tacrolimus (start Day +5) + MMF (start Day +5) — taper MMF often at Day +35, then CNI by Day +180 |
| ⚠ Conditioning Interaction | If Cy used in conditioning (e.g., Cy+TBI) AND PTCy planned: CAREFULLY evaluate total Cy dose — cumulative cardiac toxicity and hemorrhagic cystitis risk. |
| ⚠ Melphalan Interaction | If Mel used in conditioning + PTCy: carefully evaluate melphalan dose (NCCN footnote). PTCy pharmacokinetics may be affected. |
CNI TDM TARGETS: Tacrolimus typical trough 5–15 ng/mL (GVHD prophylaxis) — varies by institution and phase post-transplant. Cyclosporine 200–400 ng/mL. Check BEFORE dose and report critical values. CNIs + nephrotoxins (amphotericin, aminoglycosides, NSAIDs) → acute renal failure. Monitor CrCl and electrolytes (Mg, K) every 3–7 days in early post-transplant.
ABATACEPT PEARL: Abatacept is FDA-approved for aGVHD PROPHYLAXIS (not just treatment) in MUD and 1-allele MMUD transplantation. Combined with CNI+MTX backbone. For pharmacists: abatacept is dosed 10 mg/kg IV and has no significant drug interactions with CNIs — no TDM needed.
GVHD ACUTE & CHRONIC MANAGEMENT
More details here.
CLINICAL TRIALS
| Trial | Population | Intervention | Comparator | Key Result |
|---|---|---|---|---|
| BMT CTN 1703 (NEJM 2023) | RIC PBSC allo-HCT (MSD/MUD) | PTCy + Tac + MMF | Tac + MTX (standard) | Superior 1-yr GRFS (52.7% vs 34.9%); lower severe aGVHD + cGVHD. Category 1 for RIC. |
| REACH2 (NEJM 2020) | SR-aGVHD grade II–IV (adults ≥18y) | Ruxolitinib 10 mg BID | Investigator’s choice | Day 28 ORR 62% vs 39% (P<0.001). Median OS 11 vs 6.5 mo. FDA approved. |
| REACH3 (NEJM 2021) | SR/SD cGVHD after 1–2 lines (adult/ped ≥12y) | Ruxolitinib 10 mg BID | BAT (investigator’s choice) | ORR wk 24: 50% vs 26% (P<0.001). FFS >19 vs 6 mo. FDA approved. |
| ROCKstar (Blood 2021) | cGVHD after ≥2 prior lines | Belumosudil 200 mg QD or BID | None (single arm) | ORR 76% including lung cGVHD. DOR 54 weeks. FDA approved 2021. |
| AGAVE-201 (Blood 2023) | cGVHD after ≥2 prior lines, ≥40 kg | Axatilimab-csfr 0.3, 1, or 3 mg/kg IV q2–3 weeks | 3-arm Phase II (randomized doses) | ORR 74% at 0.3 mg/kg (best dose). FDA approved Aug 2024. |
| ABA2 (Blood 2024) | MUD and 1-allele MMUD allo-HCT (MAC/RIC) | Abatacept + CNI + MTX | CNI + MTX (placebo) | Significant reduction severe aGVHD in MMUD. FDA approved for aGVHD prophylaxis. |
| MORPHO (NEJM 2024) | FLT3-mutated AML post allo-HCT | Midostaurin 50 mg BID maintenance × 24 cycles | Placebo | Overall no significant OS/RFS benefit but RFS benefit in MRD-negative subgroup. Informative for clinical practice. |
| MC-FludT.14/L (Lancet Haematol 2020) | Older AML/MDS pts for allo-HCT | Treosulfan + Fludarabine | Busulfan + Fludarabine | Non-inferior EFS (43% vs 26%, P=0.05 for non-inferiority). Less neurotoxicity. |
| Omidubicel Phase III (Blood 2021) | UCB transplant recipients with MA conditioning | Omidubicel-onlv (ex vivo expanded UCB) | Standard UCB transplant | Neutrophil recovery 12 vs 22 days (P<0.001). Less bacterial/fungal infections (37% vs 57%, P=0.027). |
| Remestemcel-L Phase III (BBMT 2020) | Pediatric SR-aGVHD (≥2 months) | Remestemcel-L 2×10⁶ cells/kg IV BIW × 4 weeks | Pre-specified historical control (ORR 45%) | ORR 70.4% (P=0.0003). Day 100 survival 86.8% if responded. FDA approved pediatric. |
CRITICAL PHARMACIST WATCHPOINTS & CLINICAL PEARLS SUMMARY
| Category | Critical Action Item |
|---|---|
| Busulfan TDM | PK monitoring REQUIRED for oral Bu; PREFERRED for IV Bu (v1.2026). AUC target 60–100 mg×h/L. Report in mg×h/L not µM×min. Use levetiracetam NOT phenytoin for seizure prophylaxis. |
| Obese Patient Dosing | Busulfan → 25% ABW. Cyclophosphamide → lesser of TBW/IBW (Cy200) or 25% ABW if >120% IBW (Cy120). Thiotepa → 40% ABW if TBW >120% IBW. Etoposide mg/kg → 25% ABW. |
| Plerixafor Dosing | Dose on ACTUAL body weight. Max 40 mg/day. Renal adjustment: CrCl ≤50 → reduce 30% (0.16 mg/kg, max 27 mg). Administer 11h before apheresis. |
| CNI TDM | Tacrolimus trough 5–15 ng/mL (varies by phase/center). Cyclosporine 200–400 ng/mL. Monitor daily in early post-transplant → then adjust frequency. Check troughs BEFORE dosing. Electrolytes (Mg, K) essential. |
| Ibrutinib Drug Interactions | CYP3A4 substrate. Azoles (vori, posa, fluco) → INCREASE ibrutinib exposure. Dose reduce: Vori/Posa → 140 mg/day. Hold with strong CYP3A4 inhibitors if dose <140 mg possible. |
| Azithromycin Safety | NEVER prescribe azithromycin for BOS PROPHYLAXIS in HCT patients. Only for established BOS TREATMENT. Two RCTs show increased leukemia relapse + secondary neoplasms with prophylactic use. |
| Defibrotide VOD | 6.25 mg/kg IV q6h. Dose NOT adjusted for renal/hepatic. HOLD if active bleeding. Avoid concurrent anticoagulants (additive bleed risk). Not ‘deferiprone’ or ‘deferoxamine’ — confirm drug name. |
| PTCy + Cy Conditioning | If Cy used in conditioning AND PTCy planned post-transplant: FLAG total cyclophosphamide dose. Cumulative cardiotoxicity + hemorrhagic cystitis risk. Mesna coverage needed. |
| Thiotepa Skin Care | Thiotepa excreted through skin. Patient must shower every 6–8h during and for 24h after each infusion. Staff PPE during infusion. Educate nurses AND patient/caregivers. |
| Oral Beclomethasone | COMPOUNDED agent only (not commercially available). Adrenal insufficiency risk with prolonged use. Monitor symptoms. Distinguish from inhaled beclomethasone. |
| Sirolimus + TAC + MA | Combination of sirolimus + tacrolimus with MA conditioning → higher VOD/SOS risk + TMA risk. Flag if both CNI + mTOR inhibitor ordered with busulfan/TBI MA regimen. |
| Checkpoint Inhibitor Washout | Review prior therapy: PD-1/PD-L1 inhibitors or mogamulizumab within 8–12 weeks of planned conditioning start → escalated GVHD risk. Discuss with transplant team. |
| DLCO Hemoglobin Correction | Verify DLCO corrected for Hgb (Dinakara method). Uncorrected DLCO in anemic patient appears falsely low → may falsely contraindicate busulfan/carmustine. |
| Hydroxychloroquine | For cGVHD: 800 mg (12 mg/kg)/day. If used >2 years: annual ophthalmology for retinopathy. Highest doses used here are much higher than typical RA/lupus doses. |
| Ruxolitinib Dose Reduction | Hold if plt <50K or ANC <0.5K. Dose reduce to 5 mg BID if plt 50–100K. Monitor CBC biweekly in first month. JAK inhibitor immunosuppression → opportunistic infections. |
💎 CLINICAL PEARL: HCT TYPE SELECTION: Auto-HCT = cytotoxic benefit only (no GvL). Allo-HCT = GvL effect is potentially curative. Auto lower NRM but higher relapse. Allo higher NRM but lower relapse. Disease type + remission status determine which is appropriate.
💎 CLINICAL PEARL: BUSULFAN AUC TARGET: Underexposure = relapse. Overexposure = VOD/SOS + NRM. PK-guided dosing is superior to fixed-weight dosing (Anderson 2017). Optimal target undefined but most evidence supports 60–100 mg×h/L total AUC.
💎 CLINICAL PEARL: PTCy REVOLUTION: Post-transplant cyclophosphamide has made haploidentical HCT (50% HLA mismatch) feasible with outcomes comparable to MSD/MUD. It’s now the preferred prophylaxis backbone for haplo and MMUD transplants.
💎 CLINICAL PEARL: STEROID-REFRACTORY GVHD: Ruxolitinib is the ONLY FDA-approved Category 1 agent for BOTH SR-aGVHD AND SR-cGVHD. For cGVHD, ibrutinib, belumosudil, and axatilimab are additional FDA-approved options (Cat 2A). Always enroll in clinical trials first.
💎 CLINICAL PEARL: BELUMOSUDIL UNIQUENESS: Only agent with evidence for PULMONARY cGVHD response (lung ORR in ROCKstar). Unique ROCK2 kinase mechanism. For refractory BOS after ruxolitinib or ibrutinib failure.
💎 CLINICAL PEARL: VEDOLIZUMAB GI GVHD: Gut-selective mechanism (blocks α4β7 integrin → less T-cell trafficking to GI). Lower systemic immunosuppression than other 2nd-line agents → potentially fewer infections. Best used EARLY (2nd line) for steroid-refractory GI aGVHD.
💎 CLINICAL PEARL: CONDITIONING SELECTION RULE: MA → young, fit, aggressive disease (AML/ALL/MDS/CML). RIC → older, comorbid, lymphoma, CLL, plasma cell, prior auto-HCT. NMA → most fragile, indolent disease, complete reliance on GvL. HCT-CI >3 → lean toward RIC/NMA regardless of age.
💎 CLINICAL PEARL: CHIMERISM MATTERS: Declining donor chimerism post allo-HCT = early relapse signal. Complete donor chimerism (>95% in myeloid + lymphoid) = goal. Mixed chimerism may require IS taper, DLI (donor lymphocyte infusion), or pre-emptive treatment.
- McCune JS, et al. Biol Blood Marrow Transplant 2019;25:1890-1897. ↩︎
- http://hctci.org/ ↩︎